Submit an abstract to the 2018 ASCO Annual Meeting. Use the following guidelines and instructions to ensure that your abstract is entered correctly.
- Individuals may submit up to two regular abstracts as the first author.
- Individuals may submit an unlimited number of Trials in Progress abstracts.
- Individuals may serve as a coauthor on an unlimited number of abstracts.
- All types of oncology-related research are eligible for submission. Please note: case reports are not accepted.
- Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
- Interim analysis of a prospective randomized clinical trial will be considered if it is performed as planned in the original protocol and is statistically valid.
- Abstracts of clinically-related subjects should be combined into a single abstract. Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
Provide your full name, academic degree(s), institution, address, and email address. As the first author (presenting author), you will receive all future correspondence from ASCO regarding the status of your abstract. The information provided upon submission must belong to the first author.
- Agree to present the abstract if selected for presentation. (This includes being present during the scheduled time of a poster session).
- Verify that your clinical research was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Authors must assign copyright of the abstract to ASCO (unless the author is a U.S. federal employee).
- All parties involved with the abstract must abide by the Confidentiality Policy.
- All parties involved with the abstract must agree to the Prior Presentation and Publication Abstract Submission Policy.
Identification of Original Research
Indicate whether your abstract reports on original research. Original research means a systematic investigation designed for the purpose of expanding knowledge or understanding, including the analysis of data. For clarity, a clinical trial is original research under this definition, and a summary or review of prior knowledge is not original research under this definition.
Identification of Clinical Trials
Indicate whether your research is a clinical trial. A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (National Institutes of Health [NIH] Office of Extramural Research. Accessed September 15, 2017).
Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included as part of the published abstract.
Indicate whether the abstract was funded by the NIH, a pharmaceutical or biotechnology company, a tobacco company, a foundation, or another source. NIH-sponsored studies are those that receive direct NIH funding for their conduct, including cooperative group trials. If the research is funded by a pharmaceutical, biotechnology, or tobacco company, please provide a contact person at the company.
Sponsorship by ASCO Member
ASCO membership is not required to submit an abstract, however each abstract must be sponsored by an ASCO member.
- Full Members (including Early Career and International in Developing Countries) may submit and sponsor their own abstract and may sponsor other abstracts
- Allied Physician/Doctoral Scientist members may only submit and sponsor their own abstract as first author
- Members in Training may submit and sponsor their own abstract as first author with approval from their training program director
- Advanced Practice Providers, Affiliated Health Professionals, Patient Advocates, Practice Administrators, and Student/Non-Oncology Residents may submit an abstract with a sponsor signature from a Full Member
- Emeritus members retain the abstract sponsorship rights of their previous membership category
The title should objectively describe the study. Do not refer to study results or conclusions. ASCO reserves the right to edit conclusive titles.
Provide the full name, academic degree(s), institution, address, email address, and disclosure information for each coauthor. You may list up to 20 individual authors for each abstract.
Authoring Group Name
Listing a group name is optional. Do not list individual author names in this field. The group name will appear after the last author in the author string. It does not count toward the 20-author limit.
It is ASCO's policy to promote balance, independence, objectivity, and scientific rigor in all of its activities through the disclosure of financial interests and other relationships, and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in ASCO's Policy For Relationships With Companies (Journal of Clinical Oncology 2017 35:7, 796-798). All authors are expected to provide general disclosure information for 11 disclosure categories of relationship with for-profit health care companies.
The first author must obtain and include disclosure information from all coauthors. The Coauthor Disclosure Form may be used by the first author to obtain disclosure information from coauthors. The first author must enter all disclosure information through the Abstract Submitter. If an author has provided disclosure through the ASCO Disclosure Management System, the information will automatically populate in the submission site. Disclosure information for all authors will be distributed as part of ASCO’s Annual Meeting materials.
Additional Disclosure Questions for First, Last, and Corresponding Authors of Original Research
The first, last, and corresponding authors are required to answer additional questions specific to their abstract.
Restrictions for Presenting Authors
If the first author is employed by a company as defined by the CMSS Code for Interactions with Companies (see below), an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an oral abstract session or clinical science symposium. Oral abstract presenters will also be subject to the same disclosure review and management strategies as faculty, per ASCO’s Implementation Plan to Manage Relationships with Companies for CE Activities.
Company: “A for‐profit entity that develops, produces, markets, or distributes drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions. This definition is not intended to include non‐profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients.”
The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste from an existing document, or upload a text file of your abstract. Do not exceed 2,000 characters (approximately 300 to 350 words) for the total of your abstract title, body including section titles, and table. The character count does not include spaces or author names or institutions. One data table is permitted per abstract. Illustrations and figures are not permitted.
Select the most appropriate track and subcategory for the abstract (see "Submission Categories" below). When submitting your abstract, you will have the option of identifying a secondary subcategory for your abstract. The ASCO Scientific Program Committee has the authority to recategorize an abstract.
A $60 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Credit cards are the only accepted form of payment. Checks, wire transfers, and purchase orders will not be accepted. First authors from low-income countries, as defined by the World Bank, may apply for a payment waiver. These countries include: Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Democratic Republic of Congo, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Democratic People's Republic of Korea, Liberia, Madagascar, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Tanzania, Togo, Uganda and Zimbabwe. At this time, Lower-Middle Income Countries are not eligible for this waiver. Please contact us for more information.
First Author Responsibilities
The First Author Must:
- Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved parties. The Confidentiality Policy applies to both standard and late-breaking data submission from the time of abstract submission.
- Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Verify that all coauthors are aware of the contents of the abstract and support its data.
- Agree, on behalf of all coauthors, to transfer copyright to ASCO.
- Agree to present the abstract if it is selected for presentation at the ASCO Annual Meeting. (This includes being present during the scheduled time of a poster session.) If the first author is employed by a company as defined by the CMSS Code for Interactions with Companies (see Submission Requirements), an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an oral abstract session or clinical science symposium.
- Adhere to the ASCO's Policy For Relationships With Companies (Journal of Clinical Oncology 2017 35:7, 796-798) and obtain disclosure information from all coauthors using the appropriate disclosure forms.
- Comply with ASCO's conflict of interest management decisions, including the potential for slide review prior to presentation. For more information on these procedures, see ASCO’s Implementation Plan to Manage Relationships with Companies for CME Activities.
- Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors.
- Convey the Annual Meeting Abstract Policies to all coauthors and the sponsor(s) of the research.
- Enter the name of the clinical trial registry and the trial registration number if the abstract reports on a registered clinical trial.
The sponsor must:
- Be an ASCO Full Member, Allied Physician/Doctoral Scientist1 or a Member in Training2 in good standing3
- Verify the contents of the abstract and support its data
- Comply with the Confidentiality Policy
An ASCO Full Member may sponsor multiple abstracts including his or her own abstract. Affiliated Health Professionals and Allied Physicians/Doctoral Scientists can sponsor their own abstracts and Full Members can sponsor their own abstracts and the abstracts of others.
1 An ASCO Allied Physician/Doctoral Scientist may only sponsor his or her own abstract as first author.
2 An ASCO Member in Training who sponsors his or her own abstract must also obtain a signature from the training program director. (The training program director does not have to be an ASCO Member and may sign for more than one Member in Training.)
3ASCO Members who need to pay their membership dues should do so online.
For questions about ASCO membership, contact ASCO Customer Service at 703-299-0158 or 888-282-2552.
Late-Breaking Data Submissions
The ASCO late-breaking data policy allows for the submission of late-breaking data only for randomized phase II and III trials for which no preliminary data are available at the time of the abstract submission deadline (February 13, 2018), provided that the initial trial information is submitted by the February 13 deadline in a placeholder (shell) abstract submission. During abstract submission, you will be required to provide the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods for analysis.
A preplanned analysis must be scheduled after February 13 but before March 15, which is the deadline for the final, updated late-breaking data. The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline. Phase III clinical research trials for which the final data are not available by the March 15 deadline may be granted an exception to submit up to two weeks later; however, the initial trial information MUST be submitted by the February 13 deadline. Later submission may have a negative impact on placement in the program.
LATE-BREAKING DATA SUBMISSION GUIDELINES
For an abstract to be considered for late-breaking data submissions status, the first author must
- Submit an abstract, excluding the Results and Conclusions sections, by the abstract submission deadline (February 13)
- Adhere to the confidentiality policies
- Adhere to the biostatistical guidelines for phase II or III trials, with the exception of the Results and Conclusions sections
- Describe the type of data that will be submitted by the late-breaking data submission deadline, indicating the primary clinical endpoint for analysis, planned statistical plan for analysis, and date of planned analysis. (For example, “Survival data for the two treatment arms will be compared using a log-rank test.”) In general, ASCO discourages reporting of interim analysis results, unless approved by the study’s Data and Safety Monitoring Committee.
The final, updated late-breaking data should be submitted by March 15, the late-breaking submission deadline. If an updated abstract with data and analyses is not submitted, ASCO will follow up with the authors directly to determine appropriate next steps.
Phase III clinical research trials for which the final data are not available by the March 15 deadline may be granted an exception to submit up to two weeks later; however, the initial trial information MUST be submitted by the February 13 deadline. Later submission may have a negative impact on placement in the program.
Trials In Progress Abstract Submissions
ASCO recognizes the importance of bringing together researchers to discuss ongoing trials. Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.
All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a Trials in Progress submission. Trials submitted to this session are ongoing and have not reached pre-specified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
TRIALS IN PROGRESS ABSTRACT SUBMISSION GUIDELINES
- Abstracts not accepted for presentation will not be eligible for publication either in print or online.
- The nonrefundable $60 (USD) submission fee will apply.
- All conflict of interest policies apply.
- Abstracts should be organized according to two sections, Backgrounds and Methods, as described below
- Scientific background/rationale for the trial
- Preclinical and/or earlier-phase clinical data that have already been publicly presented or published may be included with references. The Trials in Progress abstract should not be used to present preclinical or earlier-phase clinical data for the first time.
- Correlative studies of particular interest
- Trial design and statistical methods, highlighting any novel aspects of the design
- Treatment or intervention planned
- Major eligibility criteria, highlighting unusual aspects
- Current enrollment without providing results or endpoints
- Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2013.”
- Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2017.”
- Phase III trials may report, “The DMC last reviewed the trial in December 2016 and suggested that the trial continue as planned.”
- Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (February 13; there are no exceptions to this criterion)
- Clinical trial registry number (required)
- The following information is not acceptable in a Trials in Progress abstract and/or poster:
- Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses. Abstracts including results or preliminary data will be rejected without further review.
- Proprietary drug names or the names of drug manufacturers in the title or body of the abstract. If necessary, you may include the proprietary drug name in parentheses directly after the generic name on first use in the body of the abstract. ASCO reserves the right to replace proprietary names with generic names to adhere to this requirement.
- Information about pricing, fees, or reimbursement related to trial participation.
- For information on the Committee's selection process for Trials in Progress submissions, please visit Abstract Selection Process.
Cancer Prevention, Hereditary Genetics, and Epidemiology
|Central Nervous System Tumors
Central Nervous System Tumors
|Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Conduct of Clinical Research
Other Novel Agents
Biomarkers and Correlative Studies from Immunotherapy Trials
Immune Checkpoint Inhibitors
|Gastrointestinal (Colorectal) Cancer
|Gastrointestinal (Noncolorectal) Cancer
Esophageal or Gastric Cancer
Small Bowel Cancer
Other GI Cancer
|Genitourinary (Nonprostate) Cancer
Other GU Cancer
|Genitourinary (Prostate) Cancer
|Head and Neck Cancer
Other (Salivary, Thyroid)
|Health Services Research, Clinical Informatics, and Quality of Care
Care Delivery/Models of Care
Disparities/Access to Care
Quality of Care/Quality Improvement
Value/Cost of Care
|Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Allogeneic Stem Cell Transplantation
Chronic Leukemia—CML and Hairy Cell
Myelodysplastic Syndromes (MDS)
Myeloproliferative Syndromes (MPD)
|Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Lymphoma
Autologous Stem Cell Transplantation for NHL, HD, or CLL
Chronic Lymphocytic Leukemia (CLL)
|Hematologic Malignancies—Plasma Cell Dyscrasia
Autologous Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Disorders
Plasma Cell Disorders
|Lung Cancer—Non-Small Cell Local-Regional/Small Cell/ Thoracic Cancers
Local-Regional Non-Small Cell Lung Cancer
Small Cell Lung Cancer
|Lung Cancer—Non-Small Cell Metastatic
Metastatic Non-Small Cell Lung Cancer
|Patient and Survivor Care
Psychosocial and Communication Research
Late and Long-Term Effects
Palliative Care and Symptom Management
Pediatric Solid Tumors
Symptom Managements/Supportive Care/Palliative Care
Gastrointestinal Stromal Tumors (GIST)
Cancer Angiogenesis and Metastases
Molecular Diagnostics and Imaging
New Targets and New Technologies